Proliferation News and Research

RSS

PDGF identified as key factor in proliferation and transformation of epicardial cells

In research that one day may lead to the discovery of how to regenerate tissue damaged by heart disease, investigators at Childrens Hospital Los Angeles have identified PDGF as a key factor in the proliferation and transformation of epicardial cells, one type of cell that surrounds heart muscle and contributes to vessels.

6 Oct 2010

Platelet derived growth factor plays role in heart regeneration

6 Oct 2010

Research finds link between calcium and cancer

A protein that pumps calcium out of cells also moonlights as a signal to get massive quantities of the stuff to flow in, according to Johns Hopkins scientists. Their discovery of this surprisingly opposite function, reported Oct. 1 in Cell, highlights the link between calcium and cancer and holds the promise of a new therapeutic target for certain breast cancers.

5 Oct 2010

New report presents scientific data on environmental causes of breast cancer

A report released today by the Breast Cancer Fund presents a comprehensive summary of the scientific data on the environmental causes of breast cancer. The report catalogues the growing evidence linking breast cancer to synthetic hormones in pharmaceuticals, cosmetics and meat; pesticides in food; solvents in household cleaning products; BPA in food containers; flame retardants in furniture; and radiation from medical treatments.

4 Oct 2010

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

4 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Roche announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time.

From Roche Sequencing and Life Science 29 Sep 2010

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Mayo Clinic, Arizona Cancer Center, and the Translational Genomics Research Institute (TGen).

29 Sep 2010

c-Met could be a potential personalized target for metastatic HCC

Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

Cylene commences CX-4945 Phase I trial in multiple myeloma

Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.

24 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

Usage of rapid response teams mask systemic problems in hospitals' care for sickest patients

The growing use of rapid response teams dispatched by hospitals to evaluate patients whose conditions have suddenly deteriorated may be masking systemic problems in how hospitals care for their sickest patients, says a prominent Johns Hopkins patient safety expert.

22 Sep 2010

Recommendations for prostate cancer prevention and treatment

In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.

21 Sep 2010

GTRI becomes Veriwave Gold Certified Partner for leveraging WaveDeploy solution

Global Technology Resources, Inc., a Colorado-based I.T. integration consulting group, has announced a formal agreement with one of its strategic partners, VeriWave Inc., making GTRI one of only a handful of Gold Certified Partners in the country. By being a Gold Certified Partner, this gives GTRI the ability to advance its healthcare professional services offerings to the next level.

21 Sep 2010

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Metabolic Solutions Development Company (MSDC), will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010. The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat. The research was conducted in tissue cultures and mice.

17 Sep 2010

Research on BMP6 protein suggests potential therapeutic target for Alzheimer's disease

Elevated levels of a growth protein in the brains of Alzheimer's disease (AD) patients is linked to impaired neurogenesis, the process by which new neurons are generated, say researchers at the University of California, San Diego in today's edition of The Journal of Neuroscience.

17 Sep 2010

Research suggests methodical approaches to control severe aggression among children with ADHD

Joseph C. Blader, Ph.D., Assistant Professor, Department of Psychiatry & Behavioral Science at Stony Brook University School of Medicine, and colleagues, found that almost half of children with attention-deficit/hyperactivity disorder whose aggressive behaviors had not been effectively controlled during routine outpatient care could achieve near absence of aggressive, explosive behavior when implementing "first-line" stimulant treatments for ADHD tailored to individual needs, along with behavioral therapy.

16 Sep 2010

Mechanism behind gene mutation leading to development of cleft palate

Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.

15 Sep 2010

Proliferation News and Research

PDGF identified as key factor in proliferation and transformation of epicardial cells

Platelet derived growth factor plays role in heart regeneration

Research finds link between calcium and cancer

New report presents scientific data on environmental causes of breast cancer

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Breast cancer breakthrough

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

c-Met could be a potential personalized target for metastatic HCC

Cylene commences CX-4945 Phase I trial in multiple myeloma

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

Scientists develop new therapy for treatment of skin, lung cancer

Usage of rapid response teams mask systemic problems in hospitals' care for sickest patients

Recommendations for prostate cancer prevention and treatment

GTRI becomes Veriwave Gold Certified Partner for leveraging WaveDeploy solution

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Research on BMP6 protein suggests potential therapeutic target for Alzheimer's disease

Research suggests methodical approaches to control severe aggression among children with ADHD

Mechanism behind gene mutation leading to development of cleft palate

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News